Desferasirox
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Iron Overload
Conditions
Iron Overload
Trial Timeline
Oct 1, 2011 → Nov 1, 2013
NCT ID
NCT01546415About Desferasirox
Desferasirox is a approved stage product being developed by Novartis for Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT01546415. Target conditions include Iron Overload.
What happened to similar drugs?
4 of 12 similar drugs in Iron Overload were approved
Approved (4) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01546415 | Approved | Completed |
Competing Products
20 competing products in Iron Overload
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KER-047 | Keros Therapeutics | Phase 2 | 17 |
| H. pylori treatment | Eisai | Phase 2/3 | 38 |
| Deferasirox | Novartis | Phase 3 | 40 |
| CSJ137 + Placebo | Novartis | Phase 1 | 29 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 2 | 35 |
| ICL670 | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 38 |
| Deferasirox | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 35 |
| deferasirox | Novartis | Approved | 43 |
| Deferasirox (ICL670) | Novartis | Phase 1/2 | 32 |
| ICL670 | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Z-213 + Saccharated Ferric Oxide | Zeria Pharmaceutical | Phase 3 | 40 |
| Z-213 | Zeria Pharmaceutical | Phase 3 | 40 |